Focalin IP Deal Between Celgene, Actavis Wins OK
By Pete Brush ( April 22, 2010, 5:32 PM EDT) -- A federal judge signed off Thursday on the dismissal of claims between plaintiffs Celgene Corp. and Novartis Pharmaceuticals Corp. and defendant Actavis South Atlantic LLC in a patent infringement suit over attention deficit hyperactivity disorder drug Focalin XR....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.